Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viridian Therapeutics, Inc. - Common Stock
(NQ:
VRDN
)
13.78
-0.46 (-3.20%)
Streaming Delayed Price
Updated: 1:53 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Viridian Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know
↗
April 21, 2026
Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.
Via
The Motley Fool
Topics
Regulatory Compliance
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
April 13, 2026
THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its...
Via
MarketMinute
Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data
April 09, 2026
In a major victory for its rare disease portfolio, Amgen (NASDAQ: AMGN) announced positive topline results on April 6, 2026, from its pivotal Phase 3 clinical trial evaluating a subcutaneous (SC)...
Via
MarketMinute
Topics
Intellectual Property
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
↗
January 07, 2025
Via
Benzinga
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
↗
December 17, 2024
Via
Benzinga
Which stocks are moving on Monday?
↗
April 06, 2026
Via
Chartmill
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
April 02, 2026
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that...
Via
MarketMinute
Topics
Intellectual Property
Which stocks are experiencing notable movement on Monday?
↗
March 30, 2026
Via
Chartmill
Here are the top movers in Monday's session.
↗
March 30, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
↗
March 30, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
March 30, 2026
Via
Chartmill
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
↗
March 21, 2026
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools
↗
March 18, 2026
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.
Via
The Motley Fool
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
↗
March 18, 2026
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Via
The Motley Fool
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
↗
March 18, 2026
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Via
The Motley Fool
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
↗
March 18, 2026
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.
Via
The Motley Fool
Topics
Regulatory Compliance
VR Adviser Adds Over 1 Million Savara Shares
↗
March 15, 2026
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
↗
February 23, 2026
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Via
The Motley Fool
Topics
Regulatory Compliance
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
↗
January 02, 2026
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
Via
The Motley Fool
Topics
Regulatory Compliance
Viridian Therapeutics Inc (NASDAQ:VRDN) Shows High-Growth Momentum and Strong Technical Setup
↗
December 18, 2025
Viridian Therapeutics (VRDN) exemplifies the Minervini SEPA strategy, combining a strong technical uptrend with explosive fundamental sales and earnings growth momentum.
Via
Chartmill
Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts
↗
October 21, 2025
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
September 29, 2025
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
↗
August 07, 2025
Via
Benzinga
Viridian (VRDN) Q2 Net Loss Widens 55%
↗
August 06, 2025
Via
The Motley Fool
What 5 Analyst Ratings Have To Say About Viridian Therapeutics
↗
May 07, 2025
Via
Benzinga
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
↗
December 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 16, 2024
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
↗
December 16, 2024
Via
Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
↗
December 16, 2024
Via
Benzinga
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
↗
December 16, 2024
The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
